| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Telomere | 41 | 2025 | 219 | 9.140 |
Why?
|
| Telomerase | 23 | 2023 | 169 | 4.850 |
Why?
|
| Dyskeratosis Congenita | 12 | 2022 | 19 | 3.140 |
Why?
|
| Saccharomyces cerevisiae Proteins | 12 | 2019 | 276 | 2.680 |
Why?
|
| Telomere-Binding Proteins | 11 | 2022 | 45 | 2.650 |
Why?
|
| Saccharomyces cerevisiae | 13 | 2019 | 424 | 2.630 |
Why?
|
| Anemia, Aplastic | 9 | 2025 | 58 | 2.090 |
Why?
|
| Telomere Shortening | 9 | 2022 | 35 | 1.910 |
Why?
|
| DNA-Binding Proteins | 14 | 2019 | 2071 | 1.820 |
Why?
|
| Telomere Homeostasis | 8 | 2024 | 46 | 1.740 |
Why?
|
| Germ-Line Mutation | 10 | 2025 | 343 | 1.700 |
Why?
|
| DNA End-Joining Repair | 5 | 2019 | 37 | 1.680 |
Why?
|
| Antigens, Nuclear | 7 | 2018 | 57 | 1.450 |
Why?
|
| Bone Marrow Diseases | 5 | 2023 | 41 | 1.310 |
Why?
|
| Intellectual Disability | 5 | 2022 | 1057 | 1.210 |
Why?
|
| Serine Proteases | 2 | 2021 | 7 | 1.180 |
Why?
|
| Microcephaly | 4 | 2021 | 331 | 1.140 |
Why?
|
| DNA Repair | 8 | 2023 | 589 | 1.130 |
Why?
|
| Fetal Growth Retardation | 3 | 2020 | 238 | 1.060 |
Why?
|
| Telomeric Repeat Binding Protein 2 | 2 | 2018 | 7 | 1.030 |
Why?
|
| Mutation | 29 | 2024 | 5965 | 1.020 |
Why?
|
| Ku Autoantigen | 7 | 2018 | 21 | 0.990 |
Why?
|
| Mutation, Missense | 4 | 2019 | 881 | 0.870 |
Why?
|
| DNA, Circular | 1 | 2023 | 17 | 0.830 |
Why?
|
| Germ Cells | 2 | 2022 | 198 | 0.820 |
Why?
|
| DNA, Fungal | 4 | 2019 | 75 | 0.790 |
Why?
|
| Exoribonucleases | 2 | 2019 | 22 | 0.760 |
Why?
|
| DNA Damage | 4 | 2025 | 517 | 0.740 |
Why?
|
| Genetic Predisposition to Disease | 11 | 2025 | 3203 | 0.730 |
Why?
|
| Mutagenesis, Insertional | 2 | 2019 | 151 | 0.720 |
Why?
|
| DNA Helicases | 4 | 2023 | 238 | 0.700 |
Why?
|
| Anemia, Diamond-Blackfan | 1 | 2020 | 10 | 0.690 |
Why?
|
| Bone Marrow | 6 | 2021 | 326 | 0.680 |
Why?
|
| Ribosomal Proteins | 1 | 2020 | 69 | 0.680 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2025 | 747 | 0.640 |
Why?
|
| Pedigree | 8 | 2021 | 1615 | 0.630 |
Why?
|
| Exocrine Pancreatic Insufficiency | 2 | 2022 | 35 | 0.620 |
Why?
|
| Myelodysplastic Syndromes | 5 | 2024 | 127 | 0.590 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2020 | 232 | 0.590 |
Why?
|
| Child, Preschool | 26 | 2025 | 14221 | 0.560 |
Why?
|
| Cell Line | 6 | 2023 | 2734 | 0.560 |
Why?
|
| Humans | 79 | 2025 | 126330 | 0.560 |
Why?
|
| Protein Binding | 11 | 2018 | 1749 | 0.540 |
Why?
|
| CD4-CD8 Ratio | 1 | 2017 | 12 | 0.540 |
Why?
|
| DNA Breaks, Double-Stranded | 2 | 2016 | 134 | 0.540 |
Why?
|
| Antibodies, Antinuclear | 1 | 2017 | 28 | 0.540 |
Why?
|
| Receptors, Thrombopoietin | 2 | 2016 | 31 | 0.530 |
Why?
|
| Transaminases | 1 | 2017 | 32 | 0.530 |
Why?
|
| Hyperbilirubinemia | 1 | 2017 | 41 | 0.530 |
Why?
|
| Inheritance Patterns | 2 | 2014 | 128 | 0.530 |
Why?
|
| Hepatitis | 1 | 2017 | 56 | 0.520 |
Why?
|
| Neoplasms | 5 | 2025 | 2807 | 0.510 |
Why?
|
| Calreticulin | 1 | 2016 | 20 | 0.510 |
Why?
|
| Thrombopoietin | 1 | 2016 | 32 | 0.510 |
Why?
|
| Thrombocythemia, Essential | 1 | 2016 | 30 | 0.500 |
Why?
|
| Janus Kinase 2 | 2 | 2016 | 131 | 0.490 |
Why?
|
| Genetic Association Studies | 4 | 2020 | 788 | 0.470 |
Why?
|
| Tryptophan | 1 | 2015 | 91 | 0.470 |
Why?
|
| Cholestasis | 1 | 2017 | 155 | 0.460 |
Why?
|
| Lipomatosis | 1 | 2014 | 16 | 0.450 |
Why?
|
| Chromosomes, Fungal | 3 | 2011 | 47 | 0.440 |
Why?
|
| Multiprotein Complexes | 1 | 2015 | 211 | 0.440 |
Why?
|
| Siblings | 3 | 2014 | 188 | 0.430 |
Why?
|
| Minisatellite Repeats | 1 | 2013 | 42 | 0.410 |
Why?
|
| Adolescent | 26 | 2025 | 19548 | 0.410 |
Why?
|
| Hematologic Neoplasms | 3 | 2024 | 281 | 0.400 |
Why?
|
| Neutropenia | 3 | 2019 | 197 | 0.400 |
Why?
|
| MicroRNAs | 1 | 2019 | 868 | 0.400 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2015 | 438 | 0.400 |
Why?
|
| Phenotype | 13 | 2024 | 4323 | 0.380 |
Why?
|
| Hematologic Diseases | 2 | 2023 | 79 | 0.370 |
Why?
|
| Syndrome | 5 | 2023 | 1122 | 0.360 |
Why?
|
| Female | 38 | 2025 | 67333 | 0.360 |
Why?
|
| Cellular Senescence | 2 | 2010 | 187 | 0.360 |
Why?
|
| Recombination, Genetic | 5 | 2013 | 449 | 0.360 |
Why?
|
| Cell Cycle Proteins | 4 | 2020 | 654 | 0.350 |
Why?
|
| Child | 30 | 2025 | 24766 | 0.350 |
Why?
|
| Male | 36 | 2025 | 62031 | 0.340 |
Why?
|
| Pancytopenia | 2 | 2023 | 41 | 0.340 |
Why?
|
| Penetrance | 2 | 2020 | 104 | 0.320 |
Why?
|
| Genomic Instability | 3 | 2022 | 232 | 0.310 |
Why?
|
| Proteins | 1 | 2014 | 1043 | 0.300 |
Why?
|
| Genetic Variation | 3 | 2020 | 1512 | 0.300 |
Why?
|
| Exodeoxyribonucleases | 2 | 2009 | 51 | 0.300 |
Why?
|
| Chromosome Disorders | 1 | 2010 | 310 | 0.300 |
Why?
|
| Amino Acid Sequence | 5 | 2020 | 2719 | 0.300 |
Why?
|
| Alleles | 7 | 2022 | 1625 | 0.300 |
Why?
|
| Leukemia, Myeloid | 2 | 2019 | 81 | 0.290 |
Why?
|
| Hematopoiesis | 2 | 2021 | 218 | 0.290 |
Why?
|
| DNA Replication | 3 | 2023 | 352 | 0.290 |
Why?
|
| Membrane Proteins | 1 | 2015 | 1551 | 0.280 |
Why?
|
| Models, Theoretical | 1 | 2009 | 370 | 0.280 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 2 | 2025 | 100 | 0.270 |
Why?
|
| Arteriovenous Fistula | 2 | 2018 | 51 | 0.270 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2024 | 564 | 0.270 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 1262 | 0.270 |
Why?
|
| Protein Structure, Tertiary | 4 | 2020 | 765 | 0.250 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2020 | 569 | 0.250 |
Why?
|
| Pulmonary Veins | 2 | 2018 | 162 | 0.250 |
Why?
|
| Immunoprecipitation | 2 | 2019 | 198 | 0.240 |
Why?
|
| Primary Myelofibrosis | 2 | 2018 | 48 | 0.240 |
Why?
|
| Ethosuximide | 1 | 2025 | 14 | 0.240 |
Why?
|
| B-Lymphocytes | 2 | 2021 | 532 | 0.230 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2025 | 47 | 0.230 |
Why?
|
| Infant | 15 | 2022 | 12681 | 0.230 |
Why?
|
| Pulmonary Artery | 2 | 2018 | 440 | 0.220 |
Why?
|
| Silent Information Regulator Proteins, Saccharomyces cerevisiae | 4 | 2017 | 9 | 0.220 |
Why?
|
| Young Adult | 11 | 2024 | 9174 | 0.220 |
Why?
|
| DNA | 2 | 2014 | 1621 | 0.220 |
Why?
|
| Chromosomal Proteins, Non-Histone | 2 | 2018 | 203 | 0.220 |
Why?
|
| Adult | 19 | 2025 | 29802 | 0.210 |
Why?
|
| Immunosuppressive Agents | 2 | 2020 | 653 | 0.210 |
Why?
|
| Osteochondrodysplasias | 2 | 2019 | 66 | 0.210 |
Why?
|
| HeLa Cells | 3 | 2023 | 796 | 0.200 |
Why?
|
| DNA Ligases | 1 | 2002 | 17 | 0.200 |
Why?
|
| Gene Order | 2 | 2014 | 80 | 0.200 |
Why?
|
| Biology | 1 | 2022 | 30 | 0.200 |
Why?
|
| Hydroxyurea | 1 | 2023 | 83 | 0.200 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2025 | 194 | 0.190 |
Why?
|
| Inflammation | 2 | 2020 | 1462 | 0.190 |
Why?
|
| Cell Division | 2 | 2003 | 762 | 0.190 |
Why?
|
| Anticonvulsants | 1 | 2025 | 384 | 0.190 |
Why?
|
| GATA2 Transcription Factor | 1 | 2021 | 39 | 0.190 |
Why?
|
| Brain Neoplasms | 3 | 2020 | 1324 | 0.190 |
Why?
|
| UDPglucose 4-Epimerase | 1 | 2021 | 7 | 0.180 |
Why?
|
| Early Detection of Cancer | 1 | 2025 | 367 | 0.180 |
Why?
|
| Galactosemias | 1 | 2021 | 15 | 0.180 |
Why?
|
| Aging | 2 | 2022 | 1208 | 0.180 |
Why?
|
| Antilymphocyte Serum | 2 | 2019 | 55 | 0.180 |
Why?
|
| Leukoplakia, Oral | 1 | 2021 | 3 | 0.180 |
Why?
|
| Receptor, EphB2 | 1 | 2021 | 9 | 0.180 |
Why?
|
| Skin Pigmentation | 1 | 2021 | 27 | 0.180 |
Why?
|
| Nails | 1 | 2021 | 20 | 0.180 |
Why?
|
| Cyclosporine | 2 | 2019 | 145 | 0.180 |
Why?
|
| Congenital Disorders of Glycosylation | 1 | 2021 | 44 | 0.180 |
Why?
|
| Cell Proliferation | 2 | 2025 | 2394 | 0.180 |
Why?
|
| Central Nervous System Cysts | 1 | 2020 | 12 | 0.170 |
Why?
|
| Anemia, Macrocytic | 1 | 2020 | 8 | 0.170 |
Why?
|
| Bulbar Palsy, Progressive | 1 | 2020 | 8 | 0.170 |
Why?
|
| Riboflavin Deficiency | 1 | 2020 | 9 | 0.170 |
Why?
|
| Dimerization | 3 | 2007 | 143 | 0.170 |
Why?
|
| Chromatin Immunoprecipitation | 2 | 2019 | 240 | 0.170 |
Why?
|
| Molecular Sequence Data | 5 | 2011 | 3901 | 0.170 |
Why?
|
| Bone Marrow Transplantation | 2 | 2020 | 566 | 0.170 |
Why?
|
| Riboflavin | 1 | 2020 | 39 | 0.170 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2020 | 55 | 0.170 |
Why?
|
| Muscle Spasticity | 1 | 2020 | 74 | 0.170 |
Why?
|
| Leukoencephalopathies | 1 | 2020 | 60 | 0.170 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2019 | 39 | 0.160 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2003 | 625 | 0.160 |
Why?
|
| Gene Deletion | 2 | 2021 | 797 | 0.160 |
Why?
|
| Calcinosis | 1 | 2020 | 183 | 0.160 |
Why?
|
| Nuclear Proteins | 5 | 2021 | 1280 | 0.150 |
Why?
|
| Ataxia | 1 | 2020 | 170 | 0.150 |
Why?
|
| Chromosomal Instability | 1 | 2019 | 57 | 0.150 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2020 | 145 | 0.150 |
Why?
|
| Megakaryocyte Progenitor Cells | 1 | 2018 | 6 | 0.150 |
Why?
|
| Metal Metabolism, Inborn Errors | 1 | 2018 | 7 | 0.150 |
Why?
|
| Telangiectasis | 1 | 2018 | 9 | 0.150 |
Why?
|
| Biological Variation, Population | 1 | 2018 | 24 | 0.150 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 190 | 0.150 |
Why?
|
| Musculoskeletal Abnormalities | 1 | 2019 | 70 | 0.150 |
Why?
|
| Arthralgia | 1 | 2018 | 56 | 0.150 |
Why?
|
| Retinal Diseases | 1 | 2020 | 175 | 0.140 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2018 | 68 | 0.140 |
Why?
|
| Twins, Monozygotic | 1 | 2018 | 118 | 0.140 |
Why?
|
| Metabolome | 1 | 2020 | 295 | 0.140 |
Why?
|
| Phosphorylation | 2 | 2020 | 1640 | 0.140 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2019 | 128 | 0.140 |
Why?
|
| DNA Mutational Analysis | 3 | 2014 | 813 | 0.140 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2021 | 546 | 0.140 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2017 | 20 | 0.140 |
Why?
|
| Molecular Docking Simulation | 1 | 2017 | 113 | 0.140 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2018 | 163 | 0.140 |
Why?
|
| Vesicular Transport Proteins | 1 | 2018 | 120 | 0.140 |
Why?
|
| Retina | 1 | 2020 | 458 | 0.140 |
Why?
|
| Models, Molecular | 2 | 2013 | 1081 | 0.140 |
Why?
|
| Down-Regulation | 1 | 2019 | 689 | 0.140 |
Why?
|
| Cytoskeletal Proteins | 1 | 2018 | 275 | 0.140 |
Why?
|
| Protein Isoforms | 1 | 2018 | 403 | 0.140 |
Why?
|
| Hypergammaglobulinemia | 1 | 2017 | 11 | 0.130 |
Why?
|
| Acute Disease | 2 | 2017 | 1103 | 0.130 |
Why?
|
| Gene Rearrangement | 1 | 2018 | 324 | 0.130 |
Why?
|
| Patient Selection | 1 | 2020 | 703 | 0.130 |
Why?
|
| NF-kappa B | 1 | 2019 | 469 | 0.130 |
Why?
|
| Hodgkin Disease | 1 | 2019 | 292 | 0.130 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2017 | 46 | 0.130 |
Why?
|
| Transcription Factors | 3 | 2023 | 2618 | 0.130 |
Why?
|
| Liver Failure | 1 | 2017 | 89 | 0.130 |
Why?
|
| Androgens | 1 | 2018 | 280 | 0.130 |
Why?
|
| Platelet Count | 1 | 2016 | 137 | 0.130 |
Why?
|
| CRISPR-Cas Systems | 1 | 2018 | 259 | 0.120 |
Why?
|
| Family | 2 | 2016 | 566 | 0.120 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2016 | 73 | 0.120 |
Why?
|
| Quinolinic Acid | 1 | 2015 | 11 | 0.120 |
Why?
|
| Liver Transplantation | 1 | 2024 | 1077 | 0.120 |
Why?
|
| Amino Acid Transport Systems | 1 | 2015 | 9 | 0.120 |
Why?
|
| Seizures | 1 | 2020 | 873 | 0.120 |
Why?
|
| Amino Acid Substitution | 2 | 2020 | 403 | 0.120 |
Why?
|
| NAD | 1 | 2015 | 45 | 0.120 |
Why?
|
| Galactose | 1 | 2015 | 54 | 0.120 |
Why?
|
| Patients | 1 | 2016 | 121 | 0.120 |
Why?
|
| Fatal Outcome | 2 | 2018 | 364 | 0.120 |
Why?
|
| Nucleic Acid Conformation | 1 | 2015 | 188 | 0.120 |
Why?
|
| Flow Cytometry | 1 | 2017 | 803 | 0.120 |
Why?
|
| Sequence Analysis, DNA | 1 | 2021 | 1768 | 0.120 |
Why?
|
| Bleomycin | 1 | 2015 | 153 | 0.120 |
Why?
|
| Leprosy, Tuberculoid | 1 | 2014 | 7 | 0.110 |
Why?
|
| Molluscum Contagiosum | 1 | 2014 | 11 | 0.110 |
Why?
|
| Actins | 1 | 2017 | 340 | 0.110 |
Why?
|
| Prognosis | 6 | 2020 | 4742 | 0.110 |
Why?
|
| Epidermodysplasia Verruciformis | 1 | 2014 | 13 | 0.110 |
Why?
|
| Colorectal Neoplasms | 1 | 2020 | 581 | 0.110 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2015 | 167 | 0.110 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2020 | 539 | 0.110 |
Why?
|
| Protein Transport | 1 | 2015 | 371 | 0.110 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2016 | 207 | 0.110 |
Why?
|
| Mucous Membrane | 1 | 2014 | 90 | 0.110 |
Why?
|
| Radiography, Abdominal | 1 | 2014 | 48 | 0.110 |
Why?
|
| Cell Line, Transformed | 1 | 2014 | 167 | 0.110 |
Why?
|
| Neutrophils | 1 | 2016 | 383 | 0.110 |
Why?
|
| Enzyme Activation | 1 | 2015 | 631 | 0.110 |
Why?
|
| Granuloma | 1 | 2014 | 68 | 0.110 |
Why?
|
| Retrospective Studies | 8 | 2024 | 16517 | 0.110 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2014 | 106 | 0.110 |
Why?
|
| Abdomen | 1 | 2014 | 127 | 0.110 |
Why?
|
| Models, Biological | 3 | 2009 | 1469 | 0.110 |
Why?
|
| Protein Multimerization | 1 | 2013 | 123 | 0.100 |
Why?
|
| Animals | 9 | 2021 | 34533 | 0.100 |
Why?
|
| Infant, Newborn | 4 | 2020 | 8308 | 0.100 |
Why?
|
| Threonine | 1 | 2012 | 61 | 0.100 |
Why?
|
| Health Care Surveys | 1 | 2013 | 285 | 0.100 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2013 | 141 | 0.100 |
Why?
|
| Microfilament Proteins | 1 | 2014 | 280 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2020 | 2689 | 0.100 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2014 | 574 | 0.100 |
Why?
|
| Middle Aged | 9 | 2025 | 27031 | 0.100 |
Why?
|
| Killer Cells, Natural | 1 | 2014 | 330 | 0.100 |
Why?
|
| Serine | 1 | 2012 | 176 | 0.090 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2011 | 49 | 0.090 |
Why?
|
| Telomeric Repeat Binding Protein 1 | 1 | 2011 | 3 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 475 | 0.090 |
Why?
|
| Glutamine | 1 | 2012 | 215 | 0.090 |
Why?
|
| Base Sequence | 3 | 2011 | 3118 | 0.090 |
Why?
|
| Skin | 1 | 2014 | 527 | 0.090 |
Why?
|
| Genes, X-Linked | 1 | 2011 | 59 | 0.090 |
Why?
|
| Homozygote | 1 | 2013 | 549 | 0.090 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2011 | 318 | 0.090 |
Why?
|
| HLA Antigens | 2 | 2022 | 240 | 0.090 |
Why?
|
| Signal Transduction | 3 | 2021 | 4638 | 0.090 |
Why?
|
| Genes, Dominant | 1 | 2011 | 246 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 3 | 2025 | 1274 | 0.090 |
Why?
|
| Mice | 6 | 2021 | 17881 | 0.090 |
Why?
|
| Papillomavirus Infections | 1 | 2014 | 296 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2010 | 63 | 0.080 |
Why?
|
| Abdominal Neoplasms | 1 | 2010 | 32 | 0.080 |
Why?
|
| Carcinoma, Small Cell | 1 | 2010 | 51 | 0.080 |
Why?
|
| Leukemia | 2 | 2012 | 368 | 0.080 |
Why?
|
| Saccharomyces | 1 | 2009 | 12 | 0.080 |
Why?
|
| Glioma | 1 | 2014 | 515 | 0.080 |
Why?
|
| Werner Syndrome Helicase | 1 | 2009 | 3 | 0.080 |
Why?
|
| Cell Cycle | 2 | 2009 | 612 | 0.080 |
Why?
|
| Receptors, Transferrin | 1 | 2009 | 10 | 0.080 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2009 | 20 | 0.080 |
Why?
|
| Liver | 1 | 2017 | 1758 | 0.080 |
Why?
|
| HCT116 Cells | 1 | 2009 | 55 | 0.080 |
Why?
|
| Chromosome Segregation | 1 | 2009 | 61 | 0.080 |
Why?
|
| Ultrasonography | 1 | 2014 | 943 | 0.080 |
Why?
|
| Fibrosarcoma | 1 | 2009 | 26 | 0.080 |
Why?
|
| Chromosomes, Human, X | 1 | 2010 | 158 | 0.080 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2009 | 35 | 0.080 |
Why?
|
| Genes, Essential | 1 | 2009 | 41 | 0.080 |
Why?
|
| Dacarbazine | 1 | 2009 | 96 | 0.080 |
Why?
|
| RecQ Helicases | 1 | 2009 | 63 | 0.080 |
Why?
|
| Fungal Proteins | 1 | 2009 | 132 | 0.080 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2009 | 102 | 0.080 |
Why?
|
| Plasmids | 2 | 2014 | 514 | 0.080 |
Why?
|
| Benzimidazoles | 1 | 2009 | 134 | 0.070 |
Why?
|
| Radiotherapy, Conformal | 1 | 2008 | 55 | 0.070 |
Why?
|
| Exome | 3 | 2018 | 1039 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2013 | 740 | 0.070 |
Why?
|
| North America | 2 | 2021 | 245 | 0.070 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 5204 | 0.070 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2007 | 58 | 0.070 |
Why?
|
| Cell Survival | 1 | 2009 | 835 | 0.070 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2007 | 70 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2024 | 1105 | 0.070 |
Why?
|
| Radiation Injuries | 1 | 2008 | 144 | 0.070 |
Why?
|
| Meningioma | 1 | 2008 | 119 | 0.070 |
Why?
|
| Protein Structure, Secondary | 1 | 2007 | 238 | 0.070 |
Why?
|
| Genes, cdc | 1 | 2006 | 25 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2009 | 592 | 0.060 |
Why?
|
| Gene Expression | 1 | 2011 | 1560 | 0.060 |
Why?
|
| Meningeal Neoplasms | 1 | 2008 | 194 | 0.060 |
Why?
|
| Chromosome Deletion | 1 | 2009 | 656 | 0.060 |
Why?
|
| Hair Diseases | 1 | 2005 | 14 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2007 | 409 | 0.060 |
Why?
|
| Structure-Activity Relationship | 1 | 2007 | 580 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2022 | 4874 | 0.060 |
Why?
|
| RNA, Untranslated | 1 | 2005 | 115 | 0.060 |
Why?
|
| Translocation, Genetic | 2 | 2021 | 359 | 0.060 |
Why?
|
| Genotype | 2 | 2017 | 2594 | 0.060 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2004 | 48 | 0.060 |
Why?
|
| Oligonucleotide Probes | 1 | 2004 | 87 | 0.060 |
Why?
|
| Immunoglobulins | 1 | 2024 | 174 | 0.050 |
Why?
|
| Yeasts | 1 | 2003 | 43 | 0.050 |
Why?
|
| Protein Structure, Quaternary | 1 | 2003 | 96 | 0.050 |
Why?
|
| MDS1 and EVI1 Complex Locus Protein | 1 | 2023 | 1 | 0.050 |
Why?
|
| Combined Modality Therapy | 3 | 2020 | 1251 | 0.050 |
Why?
|
| Chromosome Breakage | 1 | 2003 | 167 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2024 | 12380 | 0.050 |
Why?
|
| Medulloblastoma | 1 | 2008 | 550 | 0.050 |
Why?
|
| Models, Genetic | 1 | 2006 | 764 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2019 | 3777 | 0.050 |
Why?
|
| DNA Ligase ATP | 1 | 2002 | 11 | 0.050 |
Why?
|
| Conserved Sequence | 1 | 2003 | 290 | 0.050 |
Why?
|
| HLA-B Antigens | 1 | 2022 | 28 | 0.050 |
Why?
|
| Species Specificity | 1 | 2003 | 552 | 0.050 |
Why?
|
| Genetic Counseling | 2 | 2016 | 225 | 0.050 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2003 | 664 | 0.050 |
Why?
|
| Binding Sites | 3 | 2017 | 1305 | 0.050 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2022 | 103 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 2933 | 0.050 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2021 | 137 | 0.050 |
Why?
|
| Cell Self Renewal | 1 | 2021 | 45 | 0.050 |
Why?
|
| Fetal Hemoglobin | 1 | 2021 | 28 | 0.050 |
Why?
|
| Protein Conformation | 1 | 2003 | 838 | 0.050 |
Why?
|
| Glycolipids | 1 | 2021 | 33 | 0.050 |
Why?
|
| Megakaryocytes | 1 | 2021 | 43 | 0.050 |
Why?
|
| Biomarkers | 1 | 2010 | 3153 | 0.050 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2021 | 35 | 0.040 |
Why?
|
| Leukocytes | 2 | 2017 | 213 | 0.040 |
Why?
|
| Interferons | 1 | 2021 | 128 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2016 | 902 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2021 | 1909 | 0.040 |
Why?
|
| Caspase 1 | 1 | 2020 | 43 | 0.040 |
Why?
|
| Ribosomes | 1 | 2021 | 135 | 0.040 |
Why?
|
| Interleukin-18 | 1 | 2020 | 62 | 0.040 |
Why?
|
| Polysaccharides | 1 | 2021 | 141 | 0.040 |
Why?
|
| Unrelated Donors | 1 | 2020 | 67 | 0.040 |
Why?
|
| Cellular Reprogramming | 1 | 2021 | 115 | 0.040 |
Why?
|
| Liver Diseases | 1 | 2024 | 375 | 0.040 |
Why?
|
| Genomics | 2 | 2019 | 1538 | 0.040 |
Why?
|
| Heterozygote | 2 | 2014 | 674 | 0.040 |
Why?
|
| Genetic Testing | 2 | 2019 | 1021 | 0.040 |
Why?
|
| Mice, Mutant Strains | 1 | 2020 | 387 | 0.040 |
Why?
|
| Protein Precursors | 1 | 2020 | 152 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2021 | 423 | 0.040 |
Why?
|
| Risk Factors | 1 | 2013 | 10375 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 306 | 0.040 |
Why?
|
| Eukaryotic Cells | 1 | 1998 | 31 | 0.040 |
Why?
|
| Gonadal Dysgenesis, 46,XY | 1 | 2018 | 16 | 0.040 |
Why?
|
| De Lange Syndrome | 1 | 2018 | 44 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 3 | 2014 | 1342 | 0.040 |
Why?
|
| INDEL Mutation | 1 | 2018 | 89 | 0.040 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2020 | 298 | 0.040 |
Why?
|
| Consanguinity | 1 | 2018 | 117 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2018 | 127 | 0.040 |
Why?
|
| Education | 1 | 2018 | 110 | 0.040 |
Why?
|
| Colon | 1 | 2020 | 358 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2019 | 3040 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 278 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 771 | 0.040 |
Why?
|
| Mutation Rate | 1 | 2017 | 67 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 267 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2018 | 734 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2020 | 343 | 0.030 |
Why?
|
| Zebrafish | 1 | 2019 | 383 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 1413 | 0.030 |
Why?
|
| Remission Induction | 1 | 2016 | 297 | 0.030 |
Why?
|
| Apoptosis | 1 | 2003 | 1839 | 0.030 |
Why?
|
| Carcinoma, Papillary | 1 | 1996 | 73 | 0.030 |
Why?
|
| Perfusion | 1 | 2017 | 206 | 0.030 |
Why?
|
| Disease Management | 1 | 2019 | 529 | 0.030 |
Why?
|
| Workflow | 1 | 2016 | 119 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 616 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2020 | 784 | 0.030 |
Why?
|
| Hypoxia | 1 | 2017 | 256 | 0.030 |
Why?
|
| Oligodendroglioma | 1 | 2014 | 23 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2018 | 566 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 1257 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2019 | 888 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1341 | 0.030 |
Why?
|
| RNA | 1 | 2017 | 578 | 0.030 |
Why?
|
| Gene Expression Regulation, Fungal | 1 | 2014 | 54 | 0.030 |
Why?
|
| Thyroid Neoplasms | 1 | 1996 | 199 | 0.030 |
Why?
|
| Sumoylation | 1 | 2014 | 37 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 1073 | 0.030 |
Why?
|
| Aged | 3 | 2016 | 19962 | 0.030 |
Why?
|
| Lysine | 1 | 2014 | 201 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2018 | 1029 | 0.030 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2020 | 719 | 0.030 |
Why?
|
| Immunologic Memory | 1 | 2014 | 194 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 1380 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 2900 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2014 | 779 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2012 | 194 | 0.020 |
Why?
|
| Anemia, Myelophthisic | 1 | 2012 | 2 | 0.020 |
Why?
|
| Bone Marrow Examination | 1 | 2012 | 14 | 0.020 |
Why?
|
| Reticulin | 1 | 2012 | 8 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2016 | 550 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 2068 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2003 | 4467 | 0.020 |
Why?
|
| Abnormalities, Multiple | 1 | 2018 | 962 | 0.020 |
Why?
|
| Remission, Spontaneous | 1 | 2012 | 69 | 0.020 |
Why?
|
| Splenomegaly | 1 | 2012 | 33 | 0.020 |
Why?
|
| S Phase | 1 | 2011 | 74 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2014 | 589 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2012 | 184 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 820 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 975 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2012 | 301 | 0.020 |
Why?
|
| Eosinophilia | 1 | 2012 | 102 | 0.020 |
Why?
|
| Collagen | 1 | 2012 | 319 | 0.020 |
Why?
|
| Prevalence | 1 | 2017 | 2484 | 0.020 |
Why?
|
| Age of Onset | 1 | 2012 | 608 | 0.020 |
Why?
|
| Spores, Fungal | 1 | 2009 | 15 | 0.020 |
Why?
|
| Sirtuin 2 | 1 | 2009 | 6 | 0.020 |
Why?
|
| Heterochromatin | 1 | 2009 | 47 | 0.020 |
Why?
|
| DNA Mismatch Repair | 1 | 2009 | 47 | 0.020 |
Why?
|
| Dactinomycin | 1 | 2009 | 66 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2009 | 290 | 0.020 |
Why?
|
| Epistasis, Genetic | 1 | 2009 | 94 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2009 | 228 | 0.020 |
Why?
|
| Lung | 1 | 2017 | 1508 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 2406 | 0.020 |
Why?
|
| Vincristine | 1 | 2009 | 193 | 0.020 |
Why?
|
| Leg | 1 | 2009 | 154 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2009 | 420 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 2009 | 457 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 1559 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2009 | 294 | 0.020 |
Why?
|
| Computational Biology | 1 | 2012 | 838 | 0.020 |
Why?
|
| Texas | 1 | 2016 | 3587 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 1300 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2009 | 414 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2009 | 1089 | 0.020 |
Why?
|
| Simian virus 40 | 1 | 1987 | 196 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 1712 | 0.020 |
Why?
|
| RNA, Ribosomal, 5.8S | 1 | 2005 | 5 | 0.020 |
Why?
|
| Disease Progression | 1 | 2012 | 2103 | 0.020 |
Why?
|
| Cartilage | 1 | 2005 | 48 | 0.020 |
Why?
|
| Chondrocytes | 1 | 2005 | 51 | 0.020 |
Why?
|
| RNA Stability | 1 | 2005 | 82 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 6645 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 2009 | 502 | 0.010 |
Why?
|
| Embryonic Development | 1 | 2005 | 212 | 0.010 |
Why?
|
| United States | 1 | 2019 | 10990 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 2005 | 666 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2009 | 3449 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2005 | 1014 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2012 | 3078 | 0.010 |
Why?
|
| Cytokines | 1 | 2005 | 1306 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 1789 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1996 | 152 | 0.010 |
Why?
|
| Thyroidectomy | 1 | 1996 | 104 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 1996 | 228 | 0.010 |
Why?
|
| Thyroid Gland | 1 | 1996 | 106 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1987 | 369 | 0.000 |
Why?
|
| DNA, Viral | 1 | 1987 | 479 | 0.000 |
Why?
|
| Transcription, Genetic | 1 | 1987 | 1716 | 0.000 |
Why?
|